AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
Partnership Forum: This forum identified challenges and payer needs related to the evidence for digital therapeutics. The forum explored the current market space for digital therapeutics including the evidence for the products, place in therapy, monitoring or utilization metrics and barriers that patients face in obtaining therapies.
On Sept. 14, AMCP joined a Medicaid stakeholder letter urging Congress to include language that requires 12-month continuous eligibility for children on Medicaid and the Children’s Health Insurance Program (CHIP) in the reconciliation bill.
AMCP is pleased to announce that Jennifer S. Graff, PharmD, has joined the organization as senior director, professional affairs. Dr. Graff will lead strategic efforts for AMCP’s practice-related initiatives and work to advance patient outcomes and medication management strategies.
A group of 14 health care organizations in and around Washington, D.C. issued a joint statement making COVID vaccination a condition of returning to work in their respective offices.
